[Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

PubMedID: 28241705

Zhou YD, Yang L, Han QF, Tang QB, Cheng YL, Shi JX. [Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2017;35(1):51-53.
OBJECTIVE
To investigate the clinical effect of plasma exchange (PE) versus double plasma molecular adsorption system combined with PE (DPMAS+PE) in the treatment of toxic hepatic failure.

METHODS
A total of 67 patients with toxic hepatic failure who were admitted during the same period of time were divided into PE group, DPMAS+ PE group, and control group.The 22 patients in the PE group were treated with PE alone, and the 24 patients in the DPMAS+PE group were given DPMAS combined with PE. The clinical out-come was compared between the three groups.

RESULTS
Both treatment groups had significantly higher clinical response rate and 24-week survival rate than the control group.After treatment, both treatment groups had significant reductions in the serum levels of total bilirubin (TBil) , direct bilirubin (DBil) , alanine aminotransfer-ase (ALT) , and aspartate aminotransferase (AST) , and the PE group had significant reductions in the albumin (Alb) level and activated partial thromboplastin time (APTT) (P<0. 05) ; the DPMAS+PE group showed no sig-nificant changes in the Alb level and APTT (P>0. 05). There were no significant differences in TBil, DBil, ALT, and AST between the two treatment groups after treatment (P>0. 05). After treatment, the PE group had significantly higher Alb level and APTT than the DPMAS + PE group (P<0. 05). Compared with the control group, both treatment groups had significant reductions in TBil, DBil, ALT and AST after treatment (P<0. 05).

CONCLUSION
The two artificial liver support techniques can significantly improve patients' liver function and in-crease their survival rate, and the combined artificial liver support technique can reduce the amount of plasma used.